Microfluidic HDL
Subfraction Detection Platform
The pioneer of accurate and rapid blood lipid typing testing
Exclusive innovation in China
Global First
First microfluidics product entering clinical registration stage with CE certification.
Convenience and Speed
Simple operation, 30 minutes to test 12 samples, automatic interpretation and result printing.
Clinical Testing and Reliability
Completed 3,000 clinical trials domestically, demonstrating high repeatability and reliable results.
Precision Fractionation
Micron-scale HDL, the smallest plasma lipoprotein, is difficult to separate with conventional techniques.
Internationally Leading Technology
Nano-scale reactions, high-throughput detection, automated interpretation, and patented Lab-On-A-Chip technology.
Early Detection
Identifies early cardiovascular diseases and provides preventative measures, significantly reducing cardiovascular events by 40%.
Microfluidic kit and instrument registration certificate
Microfluidic kit and instrument registration certificate
91%
Concordance
118/130
Summary -- Samples Run on Bioanalyzer and Quantimetrix Lipoprint®
Complete or Partial Agreement/Total Samples Analyzed
LDL Subclass Phenotyping – Good Agreement with Established Methods
Technology and Product Advantages
Microfluidics Technology
Microfluidics technology achieves efficient biochemical reactions and analysis by precisely controlling the flow of liquids in microchannels. Guosheng Medical holds multiple patents for microfluidics technology, including microfluidic chip electrophoresis for HDL and LDL subfraction detection.
Lab-on-a-Chip
Nanoscale Precision Reaction Upgrading
High Reproducibility, High Resolution
Microscale Chip
the world's first clinical microfluidic electrophoresis product
filling the gap in the international field of HDL subfraction testing.
Company Overview
Guosheng Medical was founded in 2016 by Chinese-American scientist Dr. Xingfei Deng, focusing on precision medicine.
The company is dedicated to the development and production of high-end precision diagnostic instruments, supporting reagent kits/consumables, and molecular gene testing raw materials (such as protease).
Guosheng Medical integrates the research and development of raw materials, reagent kits, instruments, and gene testing services, establishing itself as a national high-tech and high-growth enterprise in the field of in vitro diagnostics.
Product R&D Center - Silicon Valley
Originating from Silicon Valley, USA
2011.11
Guosheng Silicon Valley Research Base Established
-
Early-stage product development
-
Overseas product sales
Result Transformation Center - Guangzhou
Rooted in China's Development
2016.3
Guangdong Guosheng Established
-
Product transformation
-
Product sales
-
9,000 square meters of R&D, production, and clinical inspection center
Guosheng Medical R&D and Molecular Testing Center
(9,000 square meters R&D, production and clinical testing center)
Founder
Dr. Xingfei Deng
Over 20 years of product R&D/entrepreneurship experience in listed biotech companies in Silicon Valley, USA
Founder, Chairman & CEO
2000-2007: Project Leader - Agilent
(Former Fortune 500, Silicon Valley Public Company)
-
Successfully developed the world's first microarray diagnostic product.
-
DNA Microarray (aCGH) development and application in collaboration with Stanford University Cardiovascular Institute.
2007-2010: VP - Artemis/Verinata (Co-founder of three main founders)
-
Successfully developed the world's first non-invasive prenatal testing (NIPT) product (widely used in clinics by companies like BGI).
-
Acquired by Illumina (the world's largest sequencing company) in 2013 for $450 million.
2010-2014: R&D Vice President - Life Tech/Thermo Fisher
(The world's largest biotech company)
-
Led the development of semiconductor high-throughput gene sequencing (NGS) assay kits and production processes, including FDA approval for Ion PGM, and brought products to the global market.
-
University of California, San Francisco (UCSF) (Postdoctoral Fellow) (Dr. Paul Simpson)
-
McGill University (PhD)
-
Shanghai Jiao Tong University School of Medicine (Master - Infectious Immunology)
-
Over 20 years of experience in the research and industrialization of diagnostic products for multinational publicly traded companies in Silicon Valley, California. Expertise in core technologies such as gene chips, microfluidic chips, high-throughput gene sequencing chips, and liquid biopsy for tumor screening.
-
Recognized as a leading innovator and outstanding entrepreneur in Guangzhou.
-
Successfully founded two biotech companies.
-
Returned to China as the Chief Scientist of NGS at Daan Gene Co., Ltd..
Cooperation Model
Funding Cooperation Model
Enterprise Equity Investment
As a professional investment institution, such as a sovereign wealth fund, private equity fund or venture capital institution, you can directly participate in the operation and development of these enterprises and share their profits by negotiating to purchase shares of the enterprises behind our technology projects.
-
Sovereign wealth fund: a national investment institution seeking long-term stable returns.
-
Private equity fund: a medium- and long-term investor focusing on enterprises with high growth potential.
-
Venture capital fund: an early-stage investor focusing on high-tech and innovative enterprises.
-
Private investment fund: an investment institution that hopes to obtain quick returns through high-return short-term projects.
Resource Cooperation Model
Market Resource Cooperation
As a partner with market resources, you can use your own resources and customer base in the local market to jointly promote and sell technology products with us and make profits. This model is suitable for super individuals and large distributors, groups, etc.
-
Super individuals: have rich market resources, government resources and customer networks, and seek new product agency opportunities.
-
Large distributors: have extensive distribution channels and a strong customer base, and can quickly promote the marketization of new products.
-
Local high-tech enterprises: have advanced technical resources, seek cooperation to jointly develop new technologies and increase product lines.
-
Research institutions: have strong R&D capabilities, and hope to cooperate with enterprises to commercialize technological achievements.
For more cooperation models, please register your needs, we will send more technical information, and jointly explore feasibility plans